Prevalence of katG and inhA mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon

Vanessa Ninkeh Nono; Edouard Akono Nantia; Awelani Miranda Mutshembele; Sorelle Nguimfack Teagho; Yannick Willy Kamdem Simo; Brenda Shile Takong; Yvonne Josiane Djieugoue; Yannick Patrick Assolo; Suzanne Magloire Ongboulal; Stanley Nkemnji Awungafac; Sara Eyangoh; Ndivuhu Agnes Makhado; Eric Mensah; Valerie Flore Donkeng Donfack

doi:10.1101/2024.05.19.24307581

Abstract

Purpose Genetic mutations in the katG and inhA promoter regions are the main drivers of isoniazid resistance. However, the geographical distribution of isoniazid resistance-associated mutations differs. This study investigated the prevalence of katG and inhA mutations in isoniazid-resistant strains of Mycobacterium tuberculosis (MTB) clinical isolates in Cameroon.

Methods A retrospective analysis was conducted on 500 isoniazid-resistant MTB clinical isolates collected from the National Tuberculosis Reference Laboratory in Cameroon (2014 to 2020). Mutations at the katG and inhA genes were screened using the GenoType® MTBDRplus assay.

Results A total of 432 culture-positive MTB isolates were obtained. The male-to-female ratio of the patients was 52.8% to 43.1%, with an average age of 36.3±13.4 years. Isoniazid resistance was detected in 86.3% of isolates, 26% being isoniazid-monoresistant and 74% multidrug resistant. The katG S315T1 mutation was the most prevalent (69.4%). Mutations in the inhA promoter region were found in 22% of isoniazid-resistant isolates, with C-15T being the most common (16.9%). Co-mutation in both katG and inhA genes was observed in 8.6% of isoniazid-resistant isolates. Additionally, 13.7% of isolates did not exhibit mutations in the katG and inhA promoter regions.

Conclusion The study confirmed the prevalence of the katG S315T substitution as a reliable indicator of isoniazid resistance, with the inhA C-15T mutation providing additional support. However, a notable proportion of isoniazid-resistant isolates exhibited no evidence of the katG S315T and inhA promoter mutations, emphasizing the importance of understanding resistance mechanisms for effective treatment strategies and public health interventions against drug-resistant tuberculosis in the region.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Fondation Merieux

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Centre Regional Ethics Committee for Human Research of the Ministry of Public Health, Cameroon gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes